

## Product datasheet for **TL302005**

### **RHCE Human shRNA Plasmid Kit (Locus ID 6006)**

#### **Product data:**

<b>Product Type:</b>	shRNA Plasmids
<b>Product Name:</b>	RHCE Human shRNA Plasmid Kit (Locus ID 6006)
<b>Locus ID:</b>	6006
<b>Synonyms:</b>	CD240CE; RH; Rh4; RH30A; RHC; RHCe(152N); RHE; RhIVb(J); RHIXB; RHNA; RHPI; RhVI; RhVIII
<b>Vector:</b>	pGFP-C-shLenti (TR30023)
<b>E. coli Selection:</b>	Chloramphenicol (34 ug/ml)
<b>Mammalian Cell Selection:</b>	Puromycin
<b>Format:</b>	Lentiviral plasmids
<b>Components:</b>	RHCE - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 6006). 5µg purified plasmid DNA per construct 29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free.
<b>RefSeq:</b>	<a href="#">NM_020485</a> , <a href="#">NM_138616</a> , <a href="#">NM_138617</a> , <a href="#">NM_138618</a> , <a href="#">NM_001330430</a> , <a href="#">NM_020485.1</a> , <a href="#">NM_020485.2</a> , <a href="#">NM_020485.3</a> , <a href="#">NM_020485.4</a> , <a href="#">NM_138616.1</a> , <a href="#">NM_138616.2</a> , <a href="#">NM_138616.3</a> , <a href="#">NM_138617.1</a> , <a href="#">NM_138617.2</a> , <a href="#">NM_138617.3</a> , <a href="#">NM_138618.1</a> , <a href="#">NM_138618.2</a> , <a href="#">NM_138618.3</a> , <a href="#">BC075081</a> , <a href="#">BC075081.2</a> , <a href="#">BC139905</a> , <a href="#">BM684087</a> , <a href="#">NM_138616.4</a> , <a href="#">NM_020485.5</a> , <a href="#">NM_138618.5</a>
<b>UniProt ID:</b>	<a href="#">P18577</a>
<b>Summary:</b>	The Rh blood group system is the second most clinically significant of the blood groups, second only to ABO. It is also the most polymorphic of the blood groups, with variations due to deletions, gene conversions, and missense mutations. The Rh blood group includes this gene which encodes both the RhC and RhE antigens on a single polypeptide and a second gene which encodes the RhD protein. The classification of Rh-positive and Rh-negative individuals is determined by the presence or absence of the highly immunogenic RhD protein on the surface of erythrocytes. A mutation in this gene results in amorph-type Rh-null disease. Alternative splicing of this gene results in multiple transcript variants encoding several different isoforms. [provided by RefSeq, Aug 2016]
<b>shRNA Design:</b>	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact <a href="mailto:techsupport@origene.com">techsupport@origene.com</a> . If you need a special design or shRNA sequence, please utilize our <a href="#">custom shRNA service</a> .



[View online »](#)

**Performance  
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at [techsupport@origene.com](mailto:techsupport@origene.com). Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).